康辰药业 (603590.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	918.0M	915.1M	825.4M	920.0M	866.7M
Cost of Revenue	93.2M	92.3M	86.1M	101.0M	126.2M
Gross Profit	824.7M	822.9M	739.3M	819.0M	740.6M
Operating Expenses
R&D Expense	57.1M	51.9M	54.9M	94.9M	86.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	140.9M	138.7M	135.3M	110.7M	102.7M
Selling & Marketing Expense	420.3M	428.8M	418.4M	472.6M	423.2M
Other Expenses	—	—	—	—	—
Total Operating Expenses	635.7M	632.6M	610.1M	672.6M	601.3M
Cost and Expenses	728.9M	724.9M	696.2M	773.7M	727.4M
Operating Income (EBIT)	206.7M	203.0M	39.1M	143.3M	140.7M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	192.8M	189.7M	38.9M	122.7M	140.3M
Income Tax Expense	23.0M	20.3M	17.3M	(64.8M)	16.4M
Bottom Line
Net Income	168.7M	166.0M	42.2M	150.5M	101.5M
Earnings from Cont. Ops	169.8M	169.4M	21.5M	187.6M	123.9M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	168.7M	166.0M	42.2M	150.5M	101.5M
Per Share
Basic EPS	CN¥1.07	CN¥1.05	CN¥0.27	CN¥0.96	CN¥0.65
Diluted EPS	CN¥1.07	CN¥1.04	CN¥0.27	CN¥0.96	CN¥0.65
Revenue Per Share	CN¥5.83	CN¥5.79	CN¥5.28	CN¥5.87	CN¥5.55
Shares
Basic Shares Outstanding	157.4M	158.1M	156.4M	156.7M	156.1M
Diluted Shares Outstanding	157.4M	158.1M	156.4M	156.7M	156.1M
Profitability Metrics
EBITDA	—	236.6M	70.9M	179.9M	173.3M
D&A	—	33.6M	31.8M	36.6M	32.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026